Search by Drug Name or NDC
NDC 68180-0317-06 Imipramine Pamoate 150 mg/1 Details
Imipramine Pamoate 150 mg/1
Imipramine Pamoate is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Lupin Pharmaceuticals, Inc.. The primary component is IMIPRAMINE PAMOATE.
MedlinePlus Drug Summary
Imipramine tablets and capsules are used to treat depression. Imipramine tablets are also used to prevent bedwetting in children. Imipramine is in a class of medications called tricyclic antidepressants. It treats depression by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance. There is not enough information to explain how imipramine prevents bedwetting.
Related Packages: 68180-0317-06Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Imipramine
Product Information
NDC | 68180-0317 |
---|---|
Product ID | 68180-317_8f335412-54c9-428f-afac-c0bdae6384b8 |
Associated GPIs | 58200050200120 |
GCN Sequence Number | 046077 |
GCN Sequence Number Description | imipramine pamoate CAPSULE 150 MG ORAL |
HIC3 | H2U |
HIC3 Description | TRICYCLIC ANTIDEPRESSANTS,REL.NON-SEL.REUPT-INHIB |
GCN | 16553 |
HICL Sequence Number | 001642 |
HICL Sequence Number Description | IMIPRAMINE PAMOATE |
Brand/Generic | Generic |
Proprietary Name | Imipramine Pamoate |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Imipramine Pamoate |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | CAPSULE |
Route | ORAL |
Active Ingredient Strength | 150 |
Active Ingredient Units | mg/1 |
Substance Name | IMIPRAMINE PAMOATE |
Labeler Name | Lupin Pharmaceuticals, Inc. |
Pharmaceutical Class | Tricyclic Antidepressant [EPC] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA090444 |
Listing Certified Through | 2024-12-31 |
Package
NDC 68180-0317-06 (68180031706)
NDC Package Code | 68180-317-06 |
---|---|
Billing NDC | 68180031706 |
Package | 30 CAPSULE in 1 BOTTLE (68180-317-06) |
Marketing Start Date | 2010-04-16 |
NDC Exclude Flag | N |
Pricing Information | N/A |